Viewing Study NCT06634667


Ignite Creation Date: 2025-12-25 @ 12:40 AM
Ignite Modification Date: 2026-01-07 @ 7:16 AM
Study NCT ID: NCT06634667
Status: NOT_YET_RECRUITING
Last Update Posted: 2024-10-10
First Post: 2024-10-06
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance
Sponsor: Hunan Province Tumor Hospital
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module